From CAR-T therapies and Artificial Intelligence (AI), to the enactment of the Drug Supply Chain Security Act (DSCSA), the past five years have been particularly transformative for the industry. Innovation in drug development has led to more complex and increasingly targeted therapies for smaller patient populations, particularly in the orphan disease and emerging cell and gene space, resulting in manufacturing challenges that require technically advanced solutions.
Accompanied by other industry leaders JoyL Silva, General Manager at Pfizer CentreOne, spoke with Contract Pharma to unpack the changes in the industry and outsourcing, what it looked like then, how it has evolved, and where it is today - providing insights on how business operations have evolved to accommodate changing industry needs and what we can expect for the future of the industry and outsourcing.
